New drug cocktail offers hope for kids with relapsed leukemia
NCT ID NCT04898894
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, selinexor and venetoclax, given together with standard chemotherapy for children and young adults whose acute myeloid leukemia (AML) has returned or not responded to treatment. The main goal is to find the safest dose and see how well the combination works at putting the cancer into remission. About 37 participants will be enrolled at St. Jude Children's Research Hospital.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cook Children's Medical Center
Fort Worth, Texas, 76104, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
Rady Children's Hospital-San Diego
San Diego, California, 92123, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
UT Southwestern/Simmons Cancer Center
Dallas, Texas, 75390, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat leukemia
- New drug aims to wake up immune system against Hard-to-Treat leukemia
- New drug combo aims to outsmart resistant leukemia
- Gentler chemo approach shows promise for tough blood cancers in older patients
- Selective immune cell removal may tame transplant complications
- Promising combo for IDH1 leukemia hits early snag – trial stopped